WILEX acquires Oncogene Science assets from Siemens Healthcare Diagnostics
Ad-hoc release pursuant to § 15 Wertpapierhandelsgesetz (German Securities Trading Act)
| PDF Download
Munich, Germany, Cambridge, MA, USA; 17 November 2010. WILEX AG (ISIN DE0006614720 / WL6 / Frankfurt Stock Exchange) today announced the signing of an agreement with Siemens Healthcare Diagnostics to acquire the assets of Oncogene Science, a commercial business entity of Siemens Healthcare Diagnostics, for approximately Euro 500,000 in cash. WILEX Inc., a wholly owned newly founded US subsidiary of WILEX AG, will license patent rights, acquire inventory including a stock of marketable diagnostic kits and will also take over the fully equipped, state-of-the-art laboratory facilities in Cambridge, MA. WILEX will also pay low-mid single digit royalties on the sales of diagnostic kits to Siemens Healthcare Diagnostics.
WILEX Inc. will employ a team of 10 current Oncogene staff, including scientists, experienced management and a sales team. The newly established unit will focus exclusively on the manufacturing, marketing and sales of diagnostic assays developed at Oncogene Science to existing and new customers in the pharmaceutical and reference laboratory industries.
Oncogene Science is a specialist in the development, manufacturing and commercialization of a variety of oncology biomarker assays with a specific focus on measuring proteins in blood. The licensed IP portfolio includes the only FDA cleared Serum HER-2/neu ELISA kit, CA IX patents covering CA IX ELISA and IHC products, as well as a uPA diagnostics patent family, which is complementary to the WILEX uPA therapeutic IP portfolio. Diagnostic kits based on this patent portfolio are manufactured at Oncogene’s ISO registered manufacturing facilities in Cambridge, MA. Siemens will retain automated platform rights for the Oncogene products, including Serum HER-2/neu and CA IX.
Please find further information in the press release, especially details to the conference calls.
Katja Arnold (CIRO)
Tel.: +49 (0)89-41 31 38-126
Fax: +49 (0)89-41 31 38-99
This communication contains certain forward-looking statements, relating to the Company’s business, which can be identified by the use of forward-looking terminology such as “estimates”, “believes”, “expects”, “may”, “will” “should” “future”, “potential” or similar expressions or by general discussion of strategy, plans or intentions of the Company. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause our actual results of operations, financial condition, performance, or achievements, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments. Given these uncertainties, prospective investors and partners are cautioned not to place undue reliance on such forward-looking statements. We disclaim any obligation to update any such forward-looking statements to reflect future events or developments.